The Rise of Perimenopause: How Tech, Politics, and Medicine Converged

Introduction: A Personal Turnaround

When Lisa Schrenk began hiking the trails of Virginia's Old Rag Mountain, she wasn't just enjoying nature—she was in crisis. As a federal IT specialist in her early forties, Schrenk had been battling depression and mood swings that doctors couldn't seem to explain or treat effectively. It wasn't until she overheard fellow hikers talking about hormone therapy that everything changed. The experience marked the beginning of what would become a life-altering journey through perimenopause care.

The shift from traditional medicine to virtual clinics wasn't just personal—it was part of a broader transformation in American healthcare. Hormone therapy, once considered too risky for widespread use due to concerns raised by a 2002 study, has now returned with a vengeance. The FDA's removal of black-box warnings and the rise of telehealth have created an environment where hormone treatments are more accessible than ever.

The Rise of Perimenopause as a Market

Perimenopause, often described as the transitional phase before menopause, affects millions of women in their forties. Unlike menopause itself, which is more easily diagnosed, perimenopause lacks definitive biomarkers—meaning that doctors must rely on symptom reporting to assess patients.

This ambiguity has been seized upon by a growing number of tech startups offering virtual care for hormonal issues. Companies like Midi, Winona, Alloy, and Evernow have capitalized on the increased demand, with some seeing traffic growth of over 400% in just a few years. Their success underscores a shift toward patient-centric medicine—where convenience, affordability, and digital accessibility drive decision-making.

"We are running into a danger zone attributing all these symptoms to perimenopause," said Stephanie Faubion, director of the Mayo Clinic's Center for Women's Health. "We need to be more cautious about what we're diagnosing and treating."

The Role of Telehealth and Marketing

Telehealth has played a central role in making hormone therapy accessible. In the post-pandemic era, patients are increasingly comfortable with virtual consultations, especially when dealing with conditions that don't require in-person attention. This comfort level has made it easier for companies like Midi to operate without traditional brick-and-mortar constraints.

Midi's strategy involves aggressive social media campaigns and influencer partnerships to reach its target audience—primarily millennial women who are more likely to trust digital sources than established medical institutions. Their messaging emphasizes empowerment and a rejection of dismissive attitudes from traditional healthcare providers.

However, this marketing approach has also drawn criticism. The company faced scrutiny for claiming that 91% of patients found relief within two months—a statement that was later revised after review by the BBB National Programs.

The Expansion of Hormone Therapy Beyond Symptoms

As the perimenopause industry grows, so does its scope. What started as a treatment for physical symptoms like hot flashes and mood swings has evolved into a broader wellness philosophy focused on longevity and preventive health. This expansion is evident in how companies like Midi market their services—not just as solutions to perimenopause symptoms, but as tools for overall health improvement.

Their approach extends beyond hormone therapy to include supplements, skincare products, and even GLP-1 medications. These additions, while profitable, raise questions about regulation and the line between medical care and consumer goods.

Regulatory Challenges and Industry Concerns

Despite the growing popularity of perimenopause care, regulatory bodies are struggling to keep pace with innovation. The lack of oversight in some virtual clinics—especially those using asynchronous prescribing methods—has raised red flags among health professionals.

Jen Gunter, a prominent ob-gyn and author of The Menopause Manifesto, has been vocal in her criticism of companies like Midi for selling unregulated supplements and products under the guise of health improvement. "Selling women inadequately studied products under the guise of closing the gaps in health care... is predatory," she wrote.

Industry leaders, including former Midi medical innovation officer Heather Hirsch, have expressed concern about how venture capital pressure can lead to profit-driven practices rather than patient-centered care. "Those companies are pressured to return that investment tenfold," Hirsch noted. "The slippery slope is slippery."

The Political Dimension of Hormone Therapy

The perimenopause revolution also intersects with broader political movements. The push for hormone therapy has been embraced by groups advocating for women's health rights, including the Make America Healthy Again movement. However, this alignment hasn't gone unnoticed in the political arena.

Robert F. Kennedy Jr., now secretary of Health and Human Services, was instrumental in pushing for the removal of FDA warnings on hormone therapy. His office's support has lent credibility to the industry's growth and opened doors for companies like Evernow to gain government backing.

This intersection of politics and medicine reflects a larger trend: the increasing influence of ideology over scientific consensus in healthcare policy.

Implications for the Future of Medicine

The emergence of platforms like Midi signals a fundamental shift in how Americans access medical care. These virtual clinics are not just offering medications—they're creating entire ecosystems around women's health that prioritize convenience, affordability, and digital engagement over traditional clinical protocols.

This evolution is both exciting and concerning. On one hand, it democratizes access to care for millions of women who might otherwise go untreated. On the other hand, it raises critical questions about quality control, safety, and long-term outcomes. As the industry continues to grow, regulators must find ways to ensure that innovation doesn't come at the expense of patient well-being.

The perimenopause movement isn't just about hormones—it's about redefining how healthcare is delivered in America. And as more women embrace these new models of care, we're witnessing the dawn of a new era in medicine—one that's shaped by technology, consumer preferences, and evolving social norms.